Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
. Precision oncology has emerged as a major focus of cancer therapeutics. This strategy is based on the hope that therapy tailored to the specific molecular features of a patient’s cancer will yield superior results, compared with the traditional “one-size-fits-all” therapeutic approach (1). Similarly, modern immunotherapeutic approaches aim to take advantage of establishing a tumor-specific immune response that will eradicate tumor cells within an individual patient and provide lasting antitumor immune memory (2). Despite promising advances in precision oncology, hypoxia (defined here as partial pressure of oxygen [pO2] <10 mmHg) remains a significant barrier to therapeutic efficacy. Small molecule–targeted agents are susceptible to cellular drug resistance mechanisms, including mechanisms driven by hypoxia (3, 4). Spatial and temporal variation in tumor hypoxia (5) may contribute to the heterogeneity in treatment response to precision oncology drug combinations (1). Hypoxia influences efficacy of immunotherapy via several mechanisms, including both innate and adaptive immunity. For example, hypoxia promotes polarization of macrophages toward the immunosuppressive M2 phenotype (6) and affects NK cell function by reducing expression of the activating receptor NKG2D (7). With respect to the adaptive immune system, hypoxia disturbs the balance between effector T cells and immunosuppressive regulatory T cells (8). Hypoxia also interferes with immune checkpoint balance by decreasing MHC class I expression by tumor cells (9), increasing programmed death ligand 1 (PD-L1) […]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022 · cited 1×
“Spatial and temporal variation in tumor hypoxia (5) may contribute to the heterogeneity in treatment response to precision oncology drug combinations (1).”
Self-citationTransport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749 · cited 3×
“In a recent review, we considered a range of strategies that improve drug delivery (14).”
InfluentialSelf-citationImmunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600
Jayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399
Sethumadhavan, S., Silva, M., Philbrook, P., Nguyen, T., Hatfield, S. M., Ohta, A., & Sitkovsky, M. V. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187314 · Cited by 119 · cited 1×
“Hypoxia also interferes with immune checkpoint balance by decreasing MHC class I expression by tumor cells (9), increasing programmed death ligand 1 (PD-L1) expression via the HIF-1 pathway, and promoting secretion of immunosuppressive cytotoxic T lymphocyte antigen–1 (CTLA-4) from tumor stromal…”
MATE2 Expression Is Associated With Cancer Cell Response to Metformin
Chowdhury, S., Yung, E., Pintilie, M., Muaddi, H., Chaib, S., Yeung, M., Fusciello, M., Sykes, J., Pitcher, B., Hagenkort, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165214 · Cited by 33
Cited by
Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy
Dunne, M., Regenold, M., & Allen, C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.007 · Cited by 150
Perspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39
Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32
Metadata
- Authors
- Dewhirst, M. W., Mowery, Y. M., Mitchell, J. B., Cherukuri, M. K., & Secomb, T. W.
- Venue
- Journal of Clinical Investigation
- Published
- 2019-01-07
- Volume
- 129
- Issue
- 2
- Pages
- 489-491
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2908226469
- Cited by
- 41
- References
- 9
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.